The role of carbohydrate antigen 19-9 in the clinical evaluation of mature cystic teratomas: an observational study at a tertiary care centre

Sumana Manohar; Shanaz Nazeen S.

doi:10.18203/2320-1770.ijrcog20233628

Authors

Sumana Manohar Department of Obstetrics and Gynaecology, Apollo Hospitals, Chennai, Tamil Nadu, India
Shanaz Nazeen S. Department of Obstetrics and Gynaecology, Apollo Hospitals, Chennai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20233628

Keywords:

MCT, Dermoid cyst, Tumour markers, CA 19-9, Size, Torsion

Abstract

Background: Carbohydrate antigen (CA) 19-9 is a tumour marker mainly used in the evaluation of gastrointestinal tract malignancies including pancreas, colon and biliary tract. Cases of ovarian tumours such as mucinous neoplasms have been reported to have high levels of CA 19-9. However, its role in the management of cystic teratomas (MCT) which are the most common benign ovarian tumours encountered in gynaecology, is not studied in depth in literature.

Methods: In our study, we observed the levels of CA 19-9 in 40 patients presenting with MCT. Its association to the cyst size, contents, laterality and torsion or rupture were documented.

Results: The various clinical parameters evaluated in our study such as larger cyst size, presence of torsion and tooth as a content had a positive association with elevated CA 19-9 levels (p<0.05). However, CA 19-9 had no significant relationship with the laterality of the cyst. Thus, CA 19-9 may serve as an important adjunct tool to ultrasonography in the management of dermoid cysts (MCT), particularly in those with larger sizes and at risk of torsion.

Conclusions: High levels of CA 19-9 can be observed in benign ovarian tumors like mature cystic teratoma (MCT) and it need not always be associated with malignancy or malignant transformation of benign tumors. Levels more than 100 IU may warrant further imaging studies to rule out gastro-intestinal pathologies. Unnecessary medical investigations or patient anxiety can be avoided in cases of moderate elevation in CA 19-9 levels.

Metrics

Metrics Loading ...

References

Artunc Ulkumen B, Goker A, Pala HG, Ordu S. Abnormal elevated CA 19-9 in the dermoid cyst: a sign of the ovarian torsion? Case Rep Obstetr Gynecol. 2013;2013.

Cho A, Kim BR, Lim SH, Park CM. Extreme elevation of CA 19-9 levels in mature cystic teratoma without any complications: A case report. Anna Med Surg. 2022;78:103803.

Sagi-Dain L, Lavie O, Auslander R, Sagi S. CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature. Int J Biological Markers. 2015;30(3):333-40.

Bhatia R, Kaur S, Mor S, Kaur N, Gupta R. Elevated serum CA 19-9 levels in dermoid cyst: a predictor of ovarian torsion and tissue necrosis? Int J Reprod Contracept Obstet Gynecol. 2019;8(6):2571-3.

Tarcoveanu E, Vasilescu A, Georgescu S, Danila N, Bradea C, Lupascu C. Laparoscopic approach to ovarian dermoid cysts. Chirurgia (Bucur). 2012;107(4):461-8.

Kyung MS, Choi JS, Hong SH, Kim HS. Elevated CA 19-9 levels in mature cystic teratoma of the ovary. The International journal of biological markers. 2009;24(1):52-6.

Williams PL, Dubbins PA, Defriend DE. Ultrasound in the diagnosis of ovarian dermoid cysts: a pictorial review of the characteristic sonographic signs. Ultrasound. 2011;19(2):85-90.

Khamene SS, Khawajah IM, Mahboobipour AA, Jafari ZA, Feizabad E, Adabi K et al. The Role of CA19-9 and CA125 in Differentiation of Ovarian Dermoid Cyst and Ovarian Malignancy: A Case-Control Study. Fertil Gynecol Androl. 2023;3(1):e137144.

Brain O, Brown LH, Suvarna S, Chapman R. Markedly elevated CA19-9 associated with benign ovarian cyst and ascites. Case Rep. 2009;2009:bcr1120081219.

Ahmadzadeh A, Shahbazian N, Arkavazi B. Examining CA 19-9 Tumor Marker in Ovarian Dermoid Cysts; A Retrospective Study. J Obstetr Gynecol Cancer Res. 2022;3(1):19-22.

Prodromidou A, Pandraklakis A, Loutradis D, Haidopoulos D. Is there a role of elevated CA 19-9 levels in the evaluation of clinical characteristics of mature cystic ovarian teratomas? A systematic review and meta-analysis. Cureus. 2019;11(12).

Var T, Tongue EA, Ugur M, Altinbas S, Tokmak A. Tumor markers panel and tumor size of ovarian dermoid tumors in reproductive age. Bratisl Lek Listy. 2012;113(2):95-8.

Ugur MG, Ozturk E, Balat O, Dikensoy E, Teke S, Aydin A. Do high levels of CA 19-9 in women with mature cystic teratomas of the ovary warrant further evaluation? Eur J Gynaec Oncol. 2012;33(2):2012

Arioz DT, Tokyol C, Sahisn FK, Koker G, Yilmaz S, Yilmazer M et al. Squamous cell carcinoma arising in a mature cystic teratoma of the ovary in young patient with elevated carbohydrate antigen 19-9. Eur J Gynaecolog Oncol. 2008;29(3):282-4.

Lin SC, Yen RF, Chen YK. Dermoid cyst with secretion of CA 19-9 detected by 18F-FDG PET/CT: A case report. Medicine. 2020;99(10).